Published in Eur Heart J on May 26, 2006
Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract (2012) 1.46
Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract (2015) 1.16
Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med (2012) 1.13
Developing a complex intervention to improve prescribing safety in primary care: mixed methods feasibility and optimisation pilot study. BMJ Open (2014) 1.03
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2013) 0.86
Ablation for atrial fibrillation in combination with left atrial appendage closure: first results of a feasibility study. J Am Heart Assoc (2012) 0.86
Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol (2008) 0.85
National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol (2007) 0.85
TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord (2010) 0.84
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J (2016) 0.84
Stroke risk in AF: do AF patterns matter? Eur Heart J (2010) 0.84
Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med (2014) 0.83
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Optimizing Atrial Fibrillation Management: From ICU and Beyond. Chest (2015) 0.82
Stroke in atrial fibrillation--hope on the horizon? J R Soc Interface (2010) 0.81
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart (2016) 0.80
Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice. PLoS One (2013) 0.79
Integrated Chronic Care Management For Patients With Atrial Fibrillation - A Rationale For Redesigning Atrial Fibrillation Care. J Atr Fibrillation (2015) 0.79
Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis. Clin Drug Investig (2012) 0.78
Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc (2014) 0.78
Stroke and bleeding risk in atrial fibrillation. Korean Circ J (2014) 0.78
Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea. J Clin Neurol (2015) 0.77
Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci (2014) 0.77
Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice. BMC Neurol (2014) 0.77
Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75
Evaluation Of Two Thromboembolism (TE) Risk Methods And Oral Anticoagulation Use Among Cardiac Device Patients With Atrial Tachyarrhythmias (AT). J Atr Fibrillation (2014) 0.75
Patients with cardiac disease: Changes observed through last decade in out-patient clinics. World J Cardiol (2013) 0.75
Stroke prevention in older adults with atrial fibrillation. CMAJ (2013) 0.75
Non vitamin K anticoagulation drugs will win the race. Neth Heart J (2016) 0.75
Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients. Interact Cardiovasc Thorac Surg (2013) 0.75
The Role of Continuous Monitoring in Atrial Fibrillation Management. Arrhythm Electrophysiol Rev (2014) 0.75
Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythm Electrophysiol Rev (2012) 0.75
Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. J Neurol Neurosurg Psychiatry (2015) 0.75
Stroke prevention in atrial fibrillation: latest clinical trials and guidelines. Pharmaceuticals (Basel) (2012) 0.75
Stroke And Bleeding Risk Assessment: Where Are We Now? J Atr Fibrillation (2014) 0.75
International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. J Am Heart Assoc (2016) 0.75
Rating the preferences for potential harms of treatments for cardiovascular disease: a survey of community-dwelling adults. Med Decis Making (2013) 0.75
Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open (2017) 0.75
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Is atrial fibrillation an inflammatory disorder? Eur Heart J (2005) 3.33
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30
The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J (2004) 3.27
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol (2010) 3.24
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol (2005) 3.12
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens (2004) 2.71
Gender differences in the management and clinical outcome of stable angina. Circulation (2006) 2.59
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57
Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? J Am Coll Cardiol (2003) 2.54
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation (2004) 2.38
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38
HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm (2010) 2.35
Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34
Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32